Johnson & Johnson earmarks $55B to boost US capacity
Johnson & Johnson is planning to invest $55 billion to build up its US footprint over the next four years, becoming the latest pharma company to pour billions into the country. As a part of ...
View ArticleAstraZeneca broadens presence in China, promising $8B+ to Harbour and Syneron
AstraZeneca is further investing in China, opening an R&D center in Beijing and inking a pair of majorly backloaded R&D deals with Chinese drug developers. The Harbour BioMed and Syneron Bio...
View ArticleAstraZeneca puts $2.5B toward first vaccine factory and second R&D site in China
AstraZeneca is again boosting its manufacturing footprint in China, this time making a $2.5 billion investment to build its first vaccine plant and second R&D facility in the country. As a part of...
View ArticleGenfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval
Plus, news about Akeso, Pulmatrix, Autolus, MacroGenics and BlissBio: Genfit completes up to €185M royalty deal: Per the agreement with HealthCare Royalty, the company gets €130 million ($141 million)...
View ArticleFDA approves Novartis’ Fabhalta in C3 glomerulopathy
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy. Fabhalta is the first drug approved specifically to treat C3...
View ArticleThe buildup to Chimerix's $935M cash exit to Jazz
Chimerix began attracting deal interest in its experimental brain tumor treatment about 18 months before it signed a $935 million cash exit to Jazz Pharmaceuticals earlier this month, according to a...
View ArticleBARDA cancels annual Industry Day
An annual gathering of industry and government officials focused on biomedical countermeasures and pandemic response has been canceled. The two-day event hosted by the Biomedical Advanced Research and...
View ArticleAlnylam hopes its ATTR-CM label will give Amvuttra an edge
Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for its newly-approved Amvuttra indication may give it an advantage over its...
View ArticleTrump think tank resurrects international drug pricing policy
President Donald Trump appears poised to bring back one of the drug pricing policies from his first term, as part of efforts to go after other countries "freeloading" on US pharma innovation. A
View ArticleLiver cancer drug combo gets its second FDA rejection
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of liver cancer. Korean biotech HLB and China-based Hengrui were applied to...
View ArticleTeenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win,...
Hello and welcome back to the new Endpoints Weekly. It was another busy week in the biopharma world and we’ve got all of the headlines for you below. We also had an
View ArticleTwo biotechs fail to beat or match Regeneron's Eylea in key trials
Opthea and Unity Biotechnology, which are both developing new drugs for eye diseases, were unable to beat or match aflibercept, the standard-of-care treatment that Regeneron markets as Eylea, in two...
View ArticleFDA's biologics chief stresses need for vaccine transmission data
Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the...
View ArticleAbbVie files suit against Genmab subsidiary ProfoundBio
AbbVie has accused a Genmab subsidiary of stealing trade secrets to build a potential competitor to its ovarian cancer treatment Elahere. In a lawsuit filed on Friday in Washington federal court,...
View ArticleTrump pharma tariffs: Details on impact and timing
President Donald Trump reiterated his plans to “at some point" put tariffs on pharmaceutical goods made outside the US, taking another step toward a trade policy that the industry has been trying to...
View ArticleTrump taps acting CDC chief Susan Monarez for permanent role
President Donald Trump has nominated acting CDC director Susan Monarez to lead the agency. He posted his decision Monday on Truth Social, saying that Monarez “understands the importance of protecting...
View ArticleMerck and Hengrui strike $2B deal for Lipoprotein(a) drug
Merck has struck a licensing deal for a cardiovascular drug with Jiangsu Hengrui Pharmaceuticals, the latest in a flood of China deals being made by US and European multinationals. Under the deal,...
View ArticleHillstar Bio raises $67M for immunology drugs
The flurry of immunology biotech launches continues. Boston-based Hillstar Bio on Tuesday became the latest immunology startup launch, unveiling a $67 million Series A round funded by Droia Ventures,...
View ArticleGSK to research whether shingles vaccine can cut dementia risk
GSK is teaming up with a pair of UK-based research bodies to conduct a “real world evidence analysis” to see if its shingles vaccine Shingrix can cut the risk of developing dementia. Together with the ...
View ArticleOphthalmology startup Character Biosciences gets $93M for genetics-based...
Seven years into its existence, Character Biosciences is ready to enter the clinic with a pair of experimental medicines targeting a bustling area of ophthalmology. The New Jersey biotech aims to treat...
View Article